Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation
- PMID: 2107057
- DOI: 10.1016/0010-7824(90)90144-k
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation
Abstract
A multicentred clinical trial was conducted in 12 countries to assess the contraceptive efficacy and side effects of a low-dose levonorgestrel-releasing vaginal ring. Contraceptive efficacy and side effects, expulsions and removals, and the relation between pregnancy rate and admission body weight of the women have been reported previously. The effect of ring use on vaginal bleeding patterns as observed from daily menstrual diaries kept by the women is the object of this paper. A total of 1005 women were fitted with the ring and 702 of them provided a menstrual diary suitable for analysis. The description of the bleeding patterns is made using a 90-day reference period approach and following the guidelines published by WHO. In addition the longest bleeding/spotting episode and longest bleeding/spotting-free interval are calculated over the entire diary length. Half of the ring users have vaginal bleeding patterns similar to normal untreated patterns. A quarter experience irregular bleeding, 10% have prolonged cycles and 10% have shortened cycles. Over one year of continuous use, there appears to be no significant trend in these patterns. Users with the worst bleeding patterns tend to discontinue first during the clinical trial and are influenced by their more recent experience of vaginal bleeding irregularities. Life-table analysis of discontinuation rates gives an underestimation of the true incidence of bleeding irregularities. Some comments are made on the limitations of the methods of analysis of menstrual diaries.
Similar articles
-
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.Contraception. 1990 Feb;41(2):105-24. doi: 10.1016/0010-7824(90)90141-h. Contraception. 1990. PMID: 2107054 Clinical Trial.
-
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.Contraception. 1990 Feb;41(2):125-41. doi: 10.1016/0010-7824(90)90142-i. Contraception. 1990. PMID: 2107055 Clinical Trial.
-
A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III-Menstrual patterns. An international comparative trial.Contraception. 1981 Oct;24(4):377-92. doi: 10.1016/0010-7824(81)90005-6. Contraception. 1981. PMID: 6797783
-
Menstrual impact of contraception.Am J Obstet Gynecol. 1994 May;170(5 Pt 2):1513-22. doi: 10.1016/s0002-9378(94)05013-1. Am J Obstet Gynecol. 1994. PMID: 8178900 Review.
-
The analysis of menstrual bleeding patterns: a review.Contraception. 1988 Aug;38(2):129-56. doi: 10.1016/0010-7824(88)90035-2. Contraception. 1988. PMID: 3048871 Review.
Cited by
-
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.Infect Dis Obstet Gynecol. 2011;2011:1-10. doi: 10.1155/2011/429403. Epub 2011 Aug 9. Infect Dis Obstet Gynecol. 2011. PMID: 21836811 Free PMC article. Review.
-
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Int J Womens Health. 2013 Oct 21;5:695-708. doi: 10.2147/IJWH.S34030. Int J Womens Health. 2013. PMID: 24174884 Free PMC article. Review.
-
High acceptability of a contraceptive vaginal ring among women in Kigali, Rwanda.PLoS One. 2018 Jun 18;13(6):e0199096. doi: 10.1371/journal.pone.0199096. eCollection 2018. PLoS One. 2018. PMID: 29912906 Free PMC article. Clinical Trial.
-
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.PLoS One. 2022 Oct 10;17(10):e0275794. doi: 10.1371/journal.pone.0275794. eCollection 2022. PLoS One. 2022. PMID: 36215267 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical